Navigation Links
Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary
Date:6/24/2008

d mean failing to realize potentially significant profits. We believe that the cost of boosting Taro's short-term cash flows in this manner is too high. Shareholder value is best optimized by cultivating Taro Ireland as a source of future revenues.

We have set out the facts as they appear to us, and are confident that when other shareholders are provided with full disclosure, they will agree entirely with us as to the long-term potential of Taro Ireland and support our objections to the proposed sale. If you feel that we have gotten the wrong impression, we are sure that you will not hesitate to provide Taro's shareholders with full disclosure as to: (i) the total investment made in Taro Ireland to date, including capitalized losses; (ii) the present asset base of Taro Ireland; (iii) Taro Ireland's financials for the last five years (including sales, expenditure and profits); and (iv) Taro Ireland's products which have been, or are in the process of being, approved by the Irish and other authorities.

2. Unfavorable Terms of Proposed Sale. In addition to the questionable rationale for the proposed sale, we have serious misgivings about the patently unfavorable terms of such sale, which include:

(i) Significant undervaluation of the Irish operations. You previously sought our permission under the Merger Agreement to sell Taro Ireland for less than the value of the real estate on which the facilities stand. Such a price would be lower than Taro Ireland's existing asset value, even without taking into account the probable future growth described above; and

(ii) A form of consideration which puts the risk on Taro. We understand that the proposed consideration includes earn-out payments based on future profits, which are contingent on the third party buyer's performance, and are not within Taro's control. Further, such amounts, if payable, will only be received at some future time. Your acceptance of such contingent payments contradicts your os
'/>"/>

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
2. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
3. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
4. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
5. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
6. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
7. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
8. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
9. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
10. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
11. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis is ... reached with Switzerland -based Kenta ... human monoclonal antibody (mAb) products, and technologies. This ... products for treatment of infections by common pathogens ... aureus , Pseudomonas aeruginosa , Acinetobacter ...
(Date:5/17/2013)... The paradigm of ‘one drug, one target’ has ... predict the adverse and therapeutic effects of a drug. ... Biology at the Genomics Laboratory, Covance, will discuss the ... when used as part of the QC process. Additionally, ... to identify key clinical targets even in complex data ...
(Date:5/17/2013)... Brea, CA (PRWEB) May 17, 2013 IAC ... DisperSol Technologies, a start up laboratory needing to set up ... be moving to a larger facility within a year’s time. ... the knowledge that the laboratory is temporary? What is efficient ... 4 Series modular workstations from IAC Industries. The planners at ...
(Date:5/16/2013)... May 16, 2013 ISPE ... A. Myers, CAE, to the newly created position ... new role, Myers will be responsible for stimulating ... production strategies, advancing the Society’s Member-led and staff-driven ... continuing to refine organizational, membership and product marketing. ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2
... CUR ) today reported financial results for the three ... ), For the second quarter of 2008, the ... share, compared to a net loss of $1,798,911 or,$(0.06) ... attributable to,common stockholders for the first six months of ...
... Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin Board: ... in the manufacture,research, development, marketing and distribution of ... first quarter of its 2009,fiscal year, ended June ... -- Net sales increased 19.5% year-over-year to ...
... Board: KDUS) announced today financial results for the second,quarter ended ... quarter of 2008 and for the same period,in 2007. Net ... to,net income of $218,960 for the same period in 2007. ... was $0.00, compared to basic net,income per share for the ...
Cached Biology Technology:Neuralstem Reports Second Quarter Financial Results and Highlights 2Neuralstem Reports Second Quarter Financial Results and Highlights 3Neuralstem Reports Second Quarter Financial Results and Highlights 4Neuralstem Reports Second Quarter Financial Results and Highlights 5Neuralstem Reports Second Quarter Financial Results and Highlights 6China-Biotics, Inc. Reports First Quarter 2009 Financial Results 2China-Biotics, Inc. Reports First Quarter 2009 Financial Results 3China-Biotics, Inc. Reports First Quarter 2009 Financial Results 4China-Biotics, Inc. Reports First Quarter 2009 Financial Results 5China-Biotics, Inc. Reports First Quarter 2009 Financial Results 6China-Biotics, Inc. Reports First Quarter 2009 Financial Results 7China-Biotics, Inc. Reports First Quarter 2009 Financial Results 8China-Biotics, Inc. Reports First Quarter 2009 Financial Results 9China-Biotics, Inc. Reports First Quarter 2009 Financial Results 10China-Biotics, Inc. Reports First Quarter 2009 Financial Results 11Cadus Reports Second Quarter 2008 Results 2Cadus Reports Second Quarter 2008 Results 3Cadus Reports Second Quarter 2008 Results 4
(Date:5/16/2013)... endothelium, the cellular layer lining the body,s blood ... hundred nanometers in thickness, this super-tenuous structure routinely ... compression to create a unique and highly dynamic ... tissues from the body,s circulatory system. , It,s ... must be physically breached to enable immune ...
(Date:5/16/2013)... about 23 million years old give unprecedented insight ... one of the most species-rich groups among the ... Professor Bettina Reichenbacher from the Division of Paleontology ... Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich / ... fossils which they assign to the group of ...
(Date:5/16/2013)... of us don,t ponder our pulses outside of the gym. ... to monitor heart health. , Zhenan Bao, a professor of ... than a dollar bill and no wider than a postage ... on the wrist, is sensitive enough to help doctors detect ... day be used to continuously track heart health and provide ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3
... WEST LAFAYETTE, Ind. - New research findings suggest that ... pulsed laser and tiny metallic "nanocages" might enable both ... system works by shining near-infrared laser pulses through the ... made of an alloy of gold and silver - ...
... University of Illinois study, omega-3 fatty acids may be good ... implications for treating male infertility. "In our experiment, we ... enzyme important in making docosahexaenoic acid (DHA). In the absence ... any misshaped sperm that can,t get where they need to ...
... The world,s largest antimony mine has become the world,s ... antimony -- an element whose environmental and biological properties ... emergent contaminant," said IU Bloomington Ph.D. student Faye Liu, ... attention to it." Used in small quantities, antimony ...
Cached Biology News:Ultrasensitive imaging method uses gold-silver 'nanocages' 2U of I study: Lack of omega-3 fatty acid linked to male infertility 2A different kind of mine disaster 2A different kind of mine disaster 3
...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... suspension array system, 100-240 V, uses multiplex ... quantitative analysis of up to 100 proteins ... The suspension array is composed of up ... which may be conjugated with a unique ...
Biology Products: